Generic Name and Formulations:
Gadoterate meglumine 0.5mmol/mL (376.9mg/mL); soln for IV inj.
Indications for DOTAREM:
For use in MRI to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity in brain (intracranial), spine and associated tissues.
Adults and Children:
0.1mmol/kg (0.2mL/kg) given as an IV bolus at a rate of 2mL/sec (adults) or 1–2mL/sec (neonates/children), followed by a normal saline flush (to ensure complete injection). Weight based dosing: see full labeling.
Increased risk of nephrogenic systemic fibrosis in patients with chronic, severe renal impairment (GFR<30mL/min/1.73m2) or acute kidney injury. Screen for acute kidney injury and other conditions that may reduce renal function. Patients at risk for chronically reduced renal function (eg, >60yrs, diabetes mellitus, chronic hypertension), estimate the GFR by lab testing. Use lowest dose necessary. Do not exceed recommended dose; allow sufficient period of time for elimination prior to re-administration. History of a reaction to contrast media, bronchial asthma and/or allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions. Have resuscitative equipment available. Avoid extravasation. Pregnancy. Nursing mothers.
Paramagnetic contrast agent (Gadolinium-based).
Nausea, headache, inj site pain, inj site coldness, rash; acute kidney injury, hypersensitivity reactions.
Single-dose vials (5mL, 10mL, 15mL, 20mL)—10; Pre-filled syringes (10mL, 15mL, 20mL)—5
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|